Veloxis Pharmaceuticals has agreed to pay more than $46 million to resolve criminal and civil allegations that it used kickbacks to drive prescriptions and purchases of Envarsus XR, its kidney-transplant drug. According to the Department of Justice, the resolution includes a deferred prosecution agreement tied to a criminal information filed in the U.S. District Court for the District of Massachusetts, underscoring the government’s continued focus on pharmaceutical marketing practices that allegedly influence prescribing decisions.

The matter is significant because it combines both criminal and civil exposure in a single healthcare-fraud resolution.

The Department of Justice has announced a $600 million settlement with Alibaba Group and AUS Merchant Services to resolve allegations that the companies failed to prevent the sale of illegal pharmaceuticals, pharmaceutical equipment, and other unlawful products on their platforms. The resolution, involving the U.S. Attorney’s Office for the District of Rhode Island, is notable not only for its size but also for what it says about the government’s enforcement posture toward large online marketplaces and payment-related service providers.

At a high level, the case reflects a familiar theory in modern platform enforcement: federal authorities are increasingly focused not just on the third-party sellers offering unlawful goods, but also on the intermediaries that allegedly enabled those transactions by failing to implement adequate controls.